Foreign Enterprises in Hainan | Dong-A Pharmaceutical: Leveraging Expanded Industry Access under the Hainan Free Trade Port to Drive Global Pharmaceutical Growth

韩国东亚制药落户海口国家高新区，聚焦医药生产与跨境医疗业务，全面享受海南自贸港医药产业开放红利。企业可适用15%企业所得税优惠，医药生产原料与设备进口实现零关税，显著压缩了生产成本。海南在生物医药、跨境医疗领域对外资全面放宽准入，突破了内地诸多行业限制。叠加自贸港辐射东南亚医药市场的区位优势，企业得以同时开拓国内与海外两大核心市场。

Dong-a Pharmaceutical Co., LTD., a century-old South Korean pharmaceutical company, has established Dong-A Pharmaceutical (Hainan) Co., Ltd.  in the Haikou National High-tech Industrial Development Zone, Hainan Province, The company fully benefits from the opportunities offered by Hainan Free Trade Port’s open biomedical policies, including a preferential corporate income tax rate of 15% and zero tariffs on imported pharmaceutical raw materials and production equipment, significantly reducing operational costs. With Hainan’s expanded market access for foreign investment, in the biomedical and cross-border medical sectors,removing many restrictions found elsewhere in Chinese mainland, combined with the Free Trade Port’s strategic location connecting Southeast Asian pharmaceutical markets, Dong-A Pharmaceutical is able to expand into both the vast Chinese market and international markets simultaneously.

Editor: Pegge Peng & Chen Xin (Internship)